Annovis Bio Inc. (ANVS) Prices 5.25M Share Offering at $4/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nvidia's revenue forecast lifts Wall Street; investors eye the Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil jumps over $2 after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
February 3, 2025 6:22 AM ESTMALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN Annovis Bio, Inc. (NYSE: ANVS) (Annovis or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share. The warrants will have an exercise price of $5.00 per share and will be immediately exercisable upon issuance for a period of five years... More
